Yesid Alvarado-Valero

20PUBLICATIONS
94CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyPredictive and prognostic markersMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Jun 11, 2026
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

|Apr 14, 2026
Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.

Jayastu Senapati, Hagop M Kantarjian, Edward Ayoub

|Dec 10, 2025
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia.

Hannah Goulart, Farhad Ravandi, Nicholas J Short

|Jun 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.

Courtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi

|Feb 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi

Pageof 4

Frequent Collaborators

16 joint publications

Courtney DiNardo

16 joint publications

Tapan M Kadia

16 joint publications

Farhad Ravandi

15 joint publications

Elias Jabbour